Genmab A/S operates in the Commercial physical research sector.
In addition to historical fundamental analyses, the complete report available to purchase compares Genmab A/S with three other
miscellaneous service companies in Europe:
Bachem Holding AG
sales of 282.50 million Swiss Francs [US$290.94 million]
of which 89%
was Active Pharmaceutical Ingredients),
(317.85 million Euro [US$350.44 million]
of which 88%
was R&D), and
Clinigen Group PLC
based in the United Kingdom
(£381.20 million [US$498.30 million]
of which 57%
was Unlicensed Medicines).
Genmab A/S reported sales of 3.03 billion Danish Kroner (US$446.33 million)
December of 2018.
increase of 27.9%
versus 2017, when the company's sales were 2.37 billion Danish Kroner.
Sales at Genmab A/S have increased during each of the previous five years
(and since 2013, sales have increased a total of 356%).